Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease
Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease
Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal’s website and are available to subscribers.
Read more on News-Medical-Net
Categories: Metastatic Breast Cancer Tags: Announces, Clinical, Disease, eliglustat, Gaucher, Genzyme, Phase, Publication, Results, tartrate, Trial
Gaucher disease: FDA approves VPRIV
Gaucher disease: FDA approves VPRIV
The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.
Read more on News-Medical-Net
Categories: Breast Cancer Symptoms Tags: approves, Disease, Gaucher, VPRIV